NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/17/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization7,460.59 mln
Float135 mln
Earnings Date11/09/2026
EPS
2.74
Solid
P / E
17.99
Moderately valued
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
13.85
Highly suspicious
1-Year Forecast
69.71
Exceptional upside
Relative Strength
79
/ 100
Strongly outperforming
Business Description
TG Therapeutics is a US-based biopharmaceutical company that develops and sells treatments for diseases driven by abnormal B-cell activity. Its flagship product, BRIUMVI, is an approved therapy for adults living with relapsing forms of multiple sclerosis. The company also has several drugs in development, including treatments targeting multiple sclerosis and certain blood-related conditions, and works alongside a number of pharmaceutical partners across global markets.
